Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02461420

Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome

The purpose of this study is to comprehensively characterize PMS using standardized medical, cognitive, and behavioral measures and to track the natural history of the syndrome using repeated longitudinal assessments. In addition, this study will be aiming to identify biomarkers using neuroimaging, including diffusion tensor imaging and identify genetic factors which contribute to diverse phenotypes in patients with PMS.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Phelan-McDermid Syndrome Autism Spectrum Disorder Child Development Disorders, Pervasive Intellectual Disability Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurodevelopmental Disorders Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Telomeric 22q13 Monosomy Syndrome

Age range

18 month and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Stanford University, Stanford, California, United States

Loading trial locations.

About this study

Phelan-McDermid syndrome (PMS) or 22q13 Deletion syndrome, caused by a loss of one copy of the SHANK3 gene, is characterized by global developmental delay/intellectual disability, motor skills deficits, delayed or absent speech, and autism spectrum disorder. The goal of this study is to understand more about the PMS phenotype and the biological pathways associated with ID and ASD in the disorder, and to establish the foundation for future clinical trials in PMS and in other ID/ASD-associated disorders that share signaling pathways with PMS.

Individuals with PMS will be asked to participate in this study if they are 18 months or older with pathogenic deletions or mutations of the SHANK3 gene at time of enrollment, as well as healthy controls. Both males and females will be asked to participate. Additionally, to be eligible for study participation, individuals' primary communicative language must be English. Parents and unaffected siblings may also be asked to consent to have blood drawn for analysis.

The study involves 3 on site visits over 2 years. Study visits involve a physical exam, medical history questions, blood work and neuropsychological assessments. A subset of participants between the ages of 2 and 11 years old will take part in the EEG portion of the study. Individuals who have a clinically indicated MRI will have an option to provide routine clinical scans for analysis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals older than 18 months of age with pathogenic deletions or mutations of the SHANK3 gene
  • English speaking individuals

Exclusion criteria

  • Has taken an investigational drug as part of another research study, within 30 days prior to study enrollment
  • For subjects involved in imaging biomarker assessment: contraindications to 3T MRI scanning, such as metal implants/non-compatible medical devices or medical conditions, including vagus nerve stimulator
  • For subjects involved in EEG/ ERP biomarker assessment: contraindications to EEG/ERP, such as uncooperative or destructive behaviors preventing lead placement or capture by ERP/VEP equipment. Under age 2 or over age 11 at the time of enrollment.
  • Unwilling or unable to comply with study procedures and assessments

Treatment and study plan

Primary outcomes

  1. Change in global cognitive ability at 12 months

    Time frame: 12 months

    Using Mullen Scales for Early Learning or Stanford Binet-5 to measure global cognitive ability

  2. Change in adaptive behavior at 12 months

    Time frame: 12 months

    Using Vineland Adaptive Behavior Scales to measure adaptive behavior

  3. Change in language abilities at 12 months

    Time frame: 12 months

    Using composite of Mullen Subscales, Vineland Subscales and Macarthur Bates Communication Developmental Inventory to measure language

  4. Change in motor functioning at 12 months

    Time frame: 12 months

    Using composite of Mullen Subscales and Vineland Subscales to measure motor functioning

  5. Change in autism symptoms at 12 months

    Time frame: 12 months

    Using composite of Autism Diagnostic Observation Schedule and Repetitive Behavior Scales-Revised to measure autism

  6. Change in global cognitive ability at 24 months

    Time frame: 24 months

    Using Mullen Scales for Early Learning or Stanford Binet-5 to measure global cognitive ability

  7. Change in adaptive behavior at 24 months

    Time frame: 24 months

    Using Vineland Adaptive Behavior Scales to measure adaptive behavior

  8. Change is language abilities at 24 months

    Time frame: 24 months

    Using composite of Mullen Subscales, Vineland Subscales and Macarthur Bates Communication Developmental Inventory to measure language

  9. Change in motor functioning at 24 months

    Time frame: 24 months

    Using composite of Mullen Subscales and Vineland Subscales to measure motor functioning

  10. Change in autism symptoms at 24 months

    Time frame: 24 months

    Using composite of Autism Diagnostic Observation Schedule and Repetitive Behavior Scales-Revised to measure autism

Sponsors and collaborators

Lead sponsor

Boston Children's Hospital

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • National Center for Advancing Translational Sciences (NCATS)
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • National Institutes of Health (NIH)
  • Office of Rare Diseases (ORD)
  • Phelan-McDermid Syndrome Foundation

Registry information

Important dates

Study start
2015
Primary completion
2025
Study completion
2026
First posted
Jun 3, 2015
Registry last updated
Feb 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.